Skip to main content

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:

Citi’s 2025 Global Healthcare Conference
Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET

Evercore 8th Annual Healthcare Conference 
Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact: 
Eva Stroynowski
ir@apellis.com
617.938.6229


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.22
+0.55 (0.24%)
AAPL  277.80
+0.83 (0.30%)
AMD  208.27
+2.14 (1.04%)
BAC  52.98
+0.51 (0.96%)
GOOG  322.66
-0.98 (-0.30%)
META  633.95
-2.27 (-0.36%)
MSFT  483.38
+6.38 (1.34%)
NVDA  180.43
+2.61 (1.47%)
ORCL  205.26
+8.23 (4.18%)
TSLA  422.27
+2.88 (0.69%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.